论文部分内容阅读
目的观察拉坦前列素降眼压疗效与前列腺素受体基因(PTGFR)多态性的相关性。方法纳入临床确诊的高眼压症患者和原发性开角型青光眼患者70例,用荧光染色原位杂交法确定PTGFR基因单核苷酸多态性(SNPs)位点rs3766355、rs3753380的基因型,分析其与拉坦前列素降眼压疗效的关系。结果 65例原发性开角型青光眼患者和高眼压症患者前列腺素受体的rs3766355位点CC+CA型的有效率高于AA型(P<0.05);rs3753380位点TT+TC型较CC型的有效率差异无统计学意义(P>0.05)。结论 PTGFR基因rs3766355位点基因多态性与拉坦前列素的降眼压疗效可能相关。
Objective To observe the relationship between the effect of latanoprost on the reduction of intraocular pressure and the polymorphism of prostaglandin receptor gene (PTGFR). Methods Seventy patients with clinically diagnosed ocular hypertension and primary open-angle glaucoma were enrolled in this study. The genotypes of rs3766355 and rs3753380 of single nucleotide polymorphisms (SNPs) of PTGFR gene were determined by fluorescence in situ hybridization , Analysis of its relationship with the efficacy of latanoprost intraocular pressure. Results The effective rate of CC + CA at rs3766355 of 65 patients with primary open angle glaucoma and patients with ocular hypertension was higher than that of AA (P <0.05). TT + TC at rs3753380 There was no significant difference in the effective rate of CC type (P> 0.05). Conclusion The gene polymorphism of PTGFR rs3766355 may be related to the antihypertensive efficacy of latanoprost.